Liu, Qingxu; Li, Yan; Zhi, Ying; Liu, Bo; Sun, Jingyong published the artcile< design, synthesis and bioactivity evaluation of novel quinazoline based KRASG12C inhibitors>, SDS of cas: 329214-79-1, the main research area is quinazoline antitumor mol docking sarcoma inhibitor.
KRAS is a member of the RAS gene family, which is involved in the regulation of human life activities. KRASG12C mutation is distributed in many tumors and has been the focus of attention. In our study, we analyzed the binding of BAY-293 to KRAS protein using mol. docking technol. We designed and synthesized 20 compounds and tested their bioactivity. At the same time, we found that compound 8P (IC50 = 2.6 ± 1.2 μM) had good inhibitory activity against the A549 cell line and compound 8e had a good inhibitory effect on the McF-7 cell line with IC50 = 5.5 ± 0.3 μM.
New Journal of Chemistry published new progress about Antitumor agents. 329214-79-1 belongs to class pyridine-derivatives, and the molecular formula is C11H16BNO2, SDS of cas: 329214-79-1.